21 CFR § 26.50 - Alert system and exchange of postmarket vigilance reports.
---identifier: "/us/cfr/t21/s26.50"source: "ecfr"legal_status: "authoritative_unofficial"title: "21 CFR § 26.50 - Alert system and exchange of postmarket vigilance reports."title_number: 21title_name: "Food and Drugs"section_number: "26.50"section_name: "Alert system and exchange of postmarket vigilance reports."chapter_name: "FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES"subchapter_number: "A"subchapter_name: "GENERAL"part_number: "26"part_name: "MUTUAL RECOGNITION OF PHARMACEUTICAL GOOD MANUFACTURING PRACTICE REPORTS, MEDICAL DEVICE QUALITY SYSTEM AUDIT REPORTS, AND CERTAIN MEDICAL DEVICE PRODUCT EVALUATION REPORTS: UNITED STATES AND THE EUROPEAN COMMUNITY"positive_law: falsecurrency: "2026-03-24"last_updated: "2026-03-24"format_version: "1.1.0"generator: "[email protected]"authority: "5 U.S.C. 552; 15 U.S.C. 1453, 1454, 1455; 18 U.S.C. 1905; 21 U.S.C. 321, 331, 351, 352, 355, 360, 360b, 360c, 360d, 360e, 360f, 360g, 360h, 360i, 360j, 360l, 360m, 371, 374, 381, 382, 383, 393; 42 U.S.C. 216, 241, 242l, 262, 264, 265."regulatory_source: "63 FR 60141, Nov. 6, 1998, unless otherwise noted."cfr_part: "26"---
Identifier
/us/cfr/t21/s26.50
Currency
2026-03-24
Positive Law
No
Updated
2026-03-24
Chapter
Food and Drug Administration, Department of Health and Human Services
# 26.50 Alert system and exchange of postmarket vigilance reports.(a) An alert system will be set up during the transition period and maintained thereafter by which the parties will notify each other when there is an immediate danger to public health. Elements of such a system will be described in an appendix F of this subpart. As part of that system, each party shall notify the other party of any confirmed problem reports, corrective actions, or recalls. These reports are regarded as part of ongoing investigations.(b) Contact points will be agreed between both parties to permit authorities to be made aware with the appropriate speed in case of quality defect, batch recalls, counterfeiting and other problems concerning quality, which could necessitate additional controls or suspension of the distribution of the product.